AU2003255671A1 - Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers - Google Patents

Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers

Info

Publication number
AU2003255671A1
AU2003255671A1 AU2003255671A AU2003255671A AU2003255671A1 AU 2003255671 A1 AU2003255671 A1 AU 2003255671A1 AU 2003255671 A AU2003255671 A AU 2003255671A AU 2003255671 A AU2003255671 A AU 2003255671A AU 2003255671 A1 AU2003255671 A1 AU 2003255671A1
Authority
AU
Australia
Prior art keywords
mab
monoclonal antibody
aurora
optionally
diagnosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003255671A
Other languages
English (en)
Other versions
AU2003255671A8 (en
Inventor
Anne Martin
Claude Prigent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Etablissement Francais du Sang
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2003255671A8 publication Critical patent/AU2003255671A8/xx
Publication of AU2003255671A1 publication Critical patent/AU2003255671A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003255671A 2002-06-12 2003-06-12 Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers Abandoned AU2003255671A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR02/07212 2002-06-12
FR0207212A FR2840905B1 (fr) 2002-06-12 2002-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
PCT/FR2003/001772 WO2003106500A1 (fr) 2002-06-12 2003-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers

Publications (2)

Publication Number Publication Date
AU2003255671A8 AU2003255671A8 (en) 2003-12-31
AU2003255671A1 true AU2003255671A1 (en) 2003-12-31

Family

ID=29595167

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003255671A Abandoned AU2003255671A1 (en) 2002-06-12 2003-06-12 Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers

Country Status (9)

Country Link
US (1) US7514231B2 (enExample)
EP (1) EP1511771B1 (enExample)
JP (1) JP4555681B2 (enExample)
AT (1) ATE420115T1 (enExample)
AU (1) AU2003255671A1 (enExample)
CA (1) CA2489214C (enExample)
DE (1) DE60325725D1 (enExample)
FR (1) FR2840905B1 (enExample)
WO (1) WO2003106500A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2239692C (en) * 1995-12-18 2008-12-16 Sugen, Inc. Diagnosis and treatment of aur-1 and/or aur-2 related disorders

Also Published As

Publication number Publication date
EP1511771B1 (fr) 2009-01-07
US20070117163A1 (en) 2007-05-24
ATE420115T1 (de) 2009-01-15
US7514231B2 (en) 2009-04-07
CA2489214C (fr) 2013-08-06
FR2840905A1 (fr) 2003-12-19
JP2006513135A (ja) 2006-04-20
AU2003255671A8 (en) 2003-12-31
EP1511771A1 (fr) 2005-03-09
FR2840905B1 (fr) 2006-07-07
CA2489214A1 (fr) 2003-12-24
WO2003106500A1 (fr) 2003-12-24
DE60325725D1 (de) 2009-02-26
JP4555681B2 (ja) 2010-10-06

Similar Documents

Publication Publication Date Title
BRPI9912227B1 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
EP2196474A3 (en) Therapeutic targets in cancer
RU2007139912A (ru) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
WO2014197937A1 (en) Methods for detecting prostate cancer
Wang et al. Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer.
Ratkaj et al. Microarray analysis of Dupuytren’s disease cells: the profibrogenic role of the TGF-β inducible p38 MAPK pathway
EP1399739A4 (en) METHOD AND KITS FOR DIAGNOSIS OF TUMOR ENGENITATION AND DETERMINATION OF RESISTANCE TO THE ANTINEOPLASTIC EFFECTS OF ANTI-STROGEN THERAPY
Rasmuson et al. Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
IL190401A0 (en) Antibodies against april as biomarkers for early prognosis of lymphoma patients
AU2003255671A1 (en) Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers
MX2013015286A (es) Metodo para predecir la respuesta clinica a quimioterapia en un sujeto con cancer.
DE50011181D1 (de) Nachweis des pyruvatkinase-isoenzyms im stuhl
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
Del Sordo et al. HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significance
WO2024252184A3 (en) Anti-cldn18_2 antibody and an in vitro diagnostic kit
WO2001098359A3 (en) Cyr61 as a target for treatment and diagnosis of breast cancer
WO2003099107A3 (en) Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient
AU2002306568A1 (en) Forms of prostate specific antigens and methods for their detection
JP2006513135A5 (enExample)
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase